Rite Aid (NYSE:RAD) reported what seemed on the surface to be a not-so-great quarter -- earnings per share dropped by half year-over-year, even though revenue increased slightly.
But health care analysts Michael Douglass and David Williamson found some intriguing opportunities for the company as it continues its now-famous turnaround. Management continues to execute on critical potential growth drivers -- opportunities the company needs if it's going to continue its meteoric rise.
In the video below, they lay out three key things Rite Aid must continue to execute on as it seeks to catch up to CVS Caremark (NYSE:CVS).
But could this opportunity trump even Rite Aid's turnaround?
As has been shown with Rite Aid's incredible turnaround, the best investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.
David Williamson has no position in any stocks mentioned. Michael Douglass has no position in any stocks mentioned. The Motley Fool recommends CVS Caremark and McKesson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.